Etentamig
Etentamig is a BCMA x CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases[1].
Product Specifications
CAS Number
2490552-52-6
Product Name Alternative
ABBV-383; TNB 383B
UNSPSC
12352203
Target
CD3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/abbv-383.html
Purity
99
Smiles
[Etentamig]
Molecular Weight
(123.8 kDa)
References & Citations
[1]D'Souza A, et al. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen x CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. J Clin Oncol. 2022 Nov 1;40 (31) :3576-3586.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Badge
Hot
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
PKSH032285-01 10 µg
Recombinant Human Creatine Kinase, Muscle/CKM Protein (His Tag)
Sign In for Pricing
View Details PKSH032285-02 50 µg
Recombinant Human Creatine Kinase, Muscle/CKM Protein (His Tag)
Sign In for Pricing
View Details